Atrial Fibrillation & Anticoagulants–StopAfib.org interviews Dr. Daniel Singer
Posted Feb 03 2012 2:55am
StopAfib.org interviews Dr. Daniel Singer of Harvard Medical School. Find more information on this topic, and Dr. Singer, at: www.stopafib.org Dr. Singer led a symposium on atrial fibrillation stroke prevention at Boston Atrial Fibrillation Symposium 2012. In this video interview, Dr. Singer shared with StopAfib.org information from that symposium. He provided an update on rivaroxaban (Xarelto), which was recently approved by the FDA, and talked about the results of the two trials of apixaban (Eliquis), AVERROES and ARISTOTLE, against aspirin and warfarin, respectively. He also mentioned edoxaban, which should finish trials in 2012, and that we now have a year of results in clinical practice with dabigatran (Pradaxa). He also mentioned that the new drugs have all shown better results than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the brain). He confirmed that patients will have a lot of new choices soon, but that cost will continue to be an issue. Dr. Singer is a Professor of Medicine at Harvard Medical School, Professor of Epidemiology at the Harvard School of Public Health, and Chief of the Clinical Epidemiology Unit at Massachusetts General Hospital.
StopAfib.org interviews Dr. Daniel Singer of Harvard Medical School. Find more information on this topic, and Dr. Singer, at: www.stopafib.org Dr. Singer led a symposium on atrial fibrillation stroke prevention at Boston Atrial Fibrillation Symposium 2012. In this video interview, Dr. Singer shared with StopAfib.org information from that symposium. He provided an update on rivaroxaban (Xarelto), which was recently approved by the FDA, and talked about the results of the two trials of apixaban (Eliquis), AVERROES and ARISTOTLE, against aspirin and warfarin, respectively. He also mentioned edoxaban, which should finish trials in 2012, and that we now have a year of results in clinical practice with dabigatran (Pradaxa). He also mentioned that the new drugs have all shown better results than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the brain). He confirmed that patients will have a lot of new choices soon, but that cost will continue to be an issue. Dr. Singer is a Professor of Medicine at Harvard Medical School, Professor of Epidemiology at the Harvard School of Public Health, and Chief of the Clinical Epidemiology Unit at Massachusetts General Hospital.